

Ycanth (cantharidin)
Effective 03/04/24

Plan	<input checked="" type="checkbox"/> MassHealth UPPL <input type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input type="checkbox"/> Pharmacy Benefit <input checked="" type="checkbox"/> Medical Benefit		
Specialty Limitations	N/A		
Contact Information	Medical and Specialty Medications		
	All Plans	Phone: 877-519-1908	Fax: 855-540-3693
Exceptions	Non-Specialty Medications		
	All Plans	Phone: 800-711-4555	Fax: 844-403-1029

Overview

Ycanth (cantharidin) is the first FDA-approved treatment for molluscum contagiosum for adults and children 2 years of age and older.

Coverage Guidelines

Authorization may be granted for members when all the following criteria are met:

1. Diagnosis of molluscum contagiosum and **ONE** of the following:
 - a. itching, pain, or bleeding associated with lesions
 - b. member is immunocompromised
 - c. concomitant bacterial infection
 - d. risk of spread to contacts (i.e., siblings, daycare)
2. Member is ≥ 2 years of age
3. Prescriber is a dermatologist or consult notes from a specialist are provided
4. Inadequate response or adverse reaction to **ONE** or contraindication to **ALL** of the following:
 - a. podofilox
 - b. cryotherapy
 - c. curettage
5. Requested dose is ≤ 8 applicators/12 weeks

Continuation of Therapy

Reauthorization when prescriber provides documentation of medical necessity for use beyond 12 weeks.

(Determine if request is for new flare of diagnosis or continuation of same episode: If new flare, use duration of authorization as with Initial approvals.)

Limitations

1. Initial approvals and reauthorizations will be granted for up to 12 weeks.

References

1. Ycanth® [package insert]. West Chester (PA): Verrica Pharmaceuticals Inc.; 2023 Jul.
2. FDA approves first treatment for molluscum contagiosum [press release on the internet]. FDA; 2023 Jul 24 [cited 2023 Nov 15]. Available from: <https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-treatment-molluscum-contagiosum>.
3. Isaacs SN. Molluscum contagiosum. In: Basow DS (Ed). UpToDate [database on the internet]. Waltham (MA): UpToDate; 2023 [cited 2023 Nov 15]. Available from: <http://www.utdol.com/utd/index.do>.

Review History

2/14/24 – Created for P&T. Adopted MH criteria. Ycanth will require PA on MB. Effective 3/4/24

